Comparative Pharmacology

Head-to-head clinical analysis: ANGIOMAX versus HEPARIN SODIUM 25 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

ANGIOMAX vs HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

ANGIOMAX

Anticoagulant

Category C

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

Anticoagulant

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.

Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa. This inhibits fibrin formation and prevents clot propagation. Dextrose 5% provides a source of calories and fluid.

Clinical Dosing

1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.

For therapeutic anticoagulation in adults, heparin is administered intravenously as an initial bolus of 80 units/kg followed by a continuous infusion of 18 units/kg/hour, with dose adjustment based on activated partial thromboplastin time (aPTT) targeting 1.5-2.5 times control. The concentration of heparin sodium 25,000 units and dextrose 5% in plastic container is typically used for continuous infusion at a rate calculated to deliver the prescribed units per hour.

Direct Interaction

None Documented